Moderna (NASDAQ:MRNA), an mRNA medicines and preventive vaccine developer, closed at $202. 63, down 17. 57%. Reports of a possible leak of late-stage personalized melanoma vaccine data sent shares lower today. Investors are waiting for the planned full Phase 3 presentation and Oct. 24 ESMO (European Society for Medical Oncology) data. Trading volume reached 49. 3M shares, coming in about 148% above its three-month average of 19. 9M shares. Moderna IPO'd in 2018 and has grown 989% since going public. The S&P 500 (SNPINDEX:^GSPC) fell 1. 22% to 7,663, and the Nasdaq Composite (NASDAQINDEX:^IXIC) lost 2. 60% to 26,009.
POLARIS INSIGHTS